PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

ICI Rechallenge After irAEs: One in Five Face Grade 3 or Higher Toxicity

immune checkpoint inhibitorsPD-1CTLA-4ipilimumabnivolumabimmune-related adverse eventsrechallengemeta-analysisobservational cohortsoncology pharmacytoxicitysupportive care Oncology

Background Information

Rechallenging ICIs after adverse events shows high toxicity but promising disease control.

Managing immune checkpoint inhibitor (ICI) rechallenge after an immune-related adverse event (irAE) is critical for optimizing cancer treatment. Index-irAE recurrence was 25.4%, any post-rechallenge irAE was 44.2%, and grade ≥ 3 irAE was 19.8%. Disease control rate was 72.7%. The study highlights frequent toxicity upon ICI rechallenge, emphasizing the need for individualized risk-benefit evaluations. ICI rechallenge post-irAE shows significant toxicity but still offers disease control, requiring careful patient assessment.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Chen X, Gao S, Zhang X, Cui R, Ma C, Yu X, Li S

Citation: Chen X, Gao S, Zhang X, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events: A Systematic Review and Meta-Analysis. Cancer medicine. 2026;15(11). doi:10.1002/cam4.72450

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.